Literature DB >> 1861545

Cellular cytotoxic function and potential in acute myelogenous leukaemia.

S H Lim1, C P Worman, A P Jewell, A H Goldstone.   

Abstract

Twenty-seven adult AML patients (13 with active disease and 14 in complete remission) were investigated for their cellular cytotoxic potential and function. All AML patients, whether with active disease or in complete remission, showed increased percentage of CD3+ lymphocytes expressing the cytotoxicity-linked cytoplasmic serine esterase, suggesting a higher than normal cytotoxic potential. However, when the cytotoxic function in these patients were analysed in terms of the natural killer and lectin-dependent cellular cytotoxicity, all AML patients, whether with active disease or in complete remission, had impaired target cell lytic activity. This paradox of cytotoxicity is most likely due to the immunosuppressive effect of the serum factor elaborated by leukaemia myeloblasts.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1861545     DOI: 10.1016/0145-2126(91)90033-p

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study.

Authors:  S H Lim; A C Newland; S Kelsey; A Bell; E Offerman; C Rist; D Gozzard; D Bareford; M P Smith; A H Goldstone
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts.

Authors:  Rifca Le Dieu; David C Taussig; Alan G Ramsay; Richard Mitter; Faridah Miraki-Moud; Rewas Fatah; Abigail M Lee; T Andrew Lister; John G Gribben
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

Review 3.  Tumor Microenvironment in Acute Myeloid Leukemia: Adjusting Niches.

Authors:  Thomas Menter; Alexandar Tzankov
Journal:  Front Immunol       Date:  2022-02-22       Impact factor: 7.561

Review 4.  Catch me if you can: how AML and its niche escape immunotherapy.

Authors:  Sarah Tettamanti; Alice Pievani; Gianpietro Dotti; Marta Serafini; Andrea Biondi
Journal:  Leukemia       Date:  2021-07-23       Impact factor: 11.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.